EA201791125A1 - Способы разработки и применения клеточных микроагрегатных элементов с минимально поляризованной функцией в тканевых приложениях с использованием эпителиальных стволовых клеток, экспрессирующих lgr4, lgr5 и lgr6 - Google Patents

Способы разработки и применения клеточных микроагрегатных элементов с минимально поляризованной функцией в тканевых приложениях с использованием эпителиальных стволовых клеток, экспрессирующих lgr4, lgr5 и lgr6

Info

Publication number
EA201791125A1
EA201791125A1 EA201791125A EA201791125A EA201791125A1 EA 201791125 A1 EA201791125 A1 EA 201791125A1 EA 201791125 A EA201791125 A EA 201791125A EA 201791125 A EA201791125 A EA 201791125A EA 201791125 A1 EA201791125 A1 EA 201791125A1
Authority
EA
Eurasian Patent Office
Prior art keywords
programs
crea
applications
cell
microagregue
Prior art date
Application number
EA201791125A
Other languages
English (en)
Russian (ru)
Inventor
Денвер М. Лок
Original Assignee
ПоларитиТЕ, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56078499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ПоларитиТЕ, ИНК. filed Critical ПоларитиТЕ, ИНК.
Publication of EA201791125A1 publication Critical patent/EA201791125A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/362—Skin, e.g. dermal papillae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201791125A 2014-12-02 2015-12-01 Способы разработки и применения клеточных микроагрегатных элементов с минимально поляризованной функцией в тканевых приложениях с использованием эпителиальных стволовых клеток, экспрессирующих lgr4, lgr5 и lgr6 EA201791125A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086526P 2014-12-02 2014-12-02
US14/954,335 US10926001B2 (en) 2014-12-02 2015-11-30 Methods related to minimally polarized functional units
PCT/US2015/063114 WO2016089825A1 (en) 2014-12-02 2015-12-01 Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells

Publications (1)

Publication Number Publication Date
EA201791125A1 true EA201791125A1 (ru) 2018-06-29

Family

ID=56078499

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791125A EA201791125A1 (ru) 2014-12-02 2015-12-01 Способы разработки и применения клеточных микроагрегатных элементов с минимально поляризованной функцией в тканевых приложениях с использованием эпителиальных стволовых клеток, экспрессирующих lgr4, lgr5 и lgr6

Country Status (21)

Country Link
US (7) US10926001B2 (cg-RX-API-DMAC7.html)
EP (2) EP3227431B1 (cg-RX-API-DMAC7.html)
JP (3) JP6791854B2 (cg-RX-API-DMAC7.html)
KR (5) KR20210043024A (cg-RX-API-DMAC7.html)
CN (1) CN107250348B (cg-RX-API-DMAC7.html)
AU (3) AU2015355187C1 (cg-RX-API-DMAC7.html)
BR (1) BR112017011808A2 (cg-RX-API-DMAC7.html)
CA (1) CA2969707C (cg-RX-API-DMAC7.html)
CO (1) CO2017006640A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170296A (cg-RX-API-DMAC7.html)
EA (1) EA201791125A1 (cg-RX-API-DMAC7.html)
GB (2) GB2569056B (cg-RX-API-DMAC7.html)
HK (1) HK1250515A1 (cg-RX-API-DMAC7.html)
IL (2) IL252613B (cg-RX-API-DMAC7.html)
MX (2) MX2017007243A (cg-RX-API-DMAC7.html)
MY (1) MY184931A (cg-RX-API-DMAC7.html)
NZ (2) NZ733433A (cg-RX-API-DMAC7.html)
PH (1) PH12017501009B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201914058QA (cg-RX-API-DMAC7.html)
WO (1) WO2016089825A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703907B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110913690A (zh) * 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
CA3088129A1 (en) * 2018-01-26 2019-08-01 Polarityte, Inc. Composite-interfacing biomaterial accelerant substrate
WO2019148143A1 (en) * 2018-01-26 2019-08-01 Polarityte, Inc. Complex living interface-coordinated self-assembling materials (clicsam)
FR3082123B1 (fr) 2018-06-07 2020-10-16 Urgo Rech Innovation Et Developpement Pansement cellularise et son procede de fabrication
JP2024006681A (ja) * 2022-07-04 2024-01-17 学校法人近畿大学 生体材料
WO2025166131A1 (en) * 2024-02-01 2025-08-07 Board Of Regents, The University Of Texas System Compositions and methods for treating bone and muscle injuries

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126881A1 (en) * 2002-09-06 2004-07-01 Vincent Ronfard Fibrin cell supports and methods of use thereof
WO2006008009A2 (en) 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6)
US20060154365A1 (en) 2004-08-30 2006-07-13 Anthony Ratcliffe Cultured three dimensional tissues and uses thereof
US8053559B2 (en) 2005-10-27 2011-11-08 Coloplast A/S Biodegradable scaffold with ECM material
US20100328320A1 (en) 2006-07-13 2010-12-30 Kerstna Juergen Medical information management in a patient information hub system
US8366723B2 (en) 2006-08-03 2013-02-05 Rassman Licensing, Llc Hair harvesting device and method with localized subsurface dermal fluid insertion
WO2008031767A1 (en) 2006-09-12 2008-03-20 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Cell culture of keratinocytes under non-differentiating conditions
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
FI20095355A0 (fi) 2009-04-01 2009-04-01 Helsingin Yliopisto Regeneroituva aktiivinen matriisi ja sen käytöt
JP2012531185A (ja) 2009-06-25 2012-12-10 株式会社 資生堂 Aff‐4を指標とした抗白髪剤のスクリーニング方法
US20110130711A1 (en) 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US20130101564A1 (en) 2010-06-30 2013-04-25 Jinxi Chen Method for preparing dermis tissue cells aggregation and uses thereof
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
JP6215216B2 (ja) 2011-10-27 2017-10-18 ウニヴェルジテート ライプチッヒ 毛包外毛根鞘からメラノサイトを誘導する方法および移植のための調製
JP6186997B2 (ja) 2012-08-07 2017-08-30 日油株式会社 塗布型帯電防止剤
US9655930B2 (en) 2012-10-01 2017-05-23 Aderans Research Institute, Inc. Compositions and methods for producing reconstituted skin
US20140106447A1 (en) 2012-10-12 2014-04-17 Mimedx Group, Inc. Compositions and methods for recruiting stem cells
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
US9592257B2 (en) 2013-10-11 2017-03-14 MWV Cell, LLC Complete human skin organ generated from culture-expanded cells
CN103550828B (zh) * 2013-10-17 2016-01-27 中国科学院动物研究所 一种基于毛囊干细胞和硅凝胶敷料的皮肤重建方法
TWI548413B (zh) 2014-11-07 2016-09-11 國立臺灣大學 誘導毛囊新生的皮膚萃取物、組合物及其用途

Also Published As

Publication number Publication date
CR20170296A (es) 2018-01-25
EP3227431B1 (en) 2025-01-29
US11266765B2 (en) 2022-03-08
WO2016089825A1 (en) 2016-06-09
EP3227431A4 (en) 2019-01-02
AU2019240603B2 (en) 2023-02-09
GB201902819D0 (en) 2019-04-17
GB2549872A (en) 2017-11-01
GB201710646D0 (en) 2017-08-16
US20160151540A1 (en) 2016-06-02
PH12017501009A1 (en) 2017-12-11
US20190046691A1 (en) 2019-02-14
US20220241464A1 (en) 2022-08-04
AU2023202857A1 (en) 2023-05-25
BR112017011808A2 (en) 2018-02-27
KR20190111167A (ko) 2019-10-01
US11338060B2 (en) 2022-05-24
US20180154044A1 (en) 2018-06-07
NZ755260A (en) 2021-12-24
IL287488B2 (en) 2023-06-01
AU2015355187B2 (en) 2019-10-03
EP3227431A1 (en) 2017-10-11
CA2969707A1 (en) 2016-06-09
AU2015355187C1 (en) 2020-02-20
EP4438128A2 (en) 2024-10-02
US12465669B2 (en) 2025-11-11
EP4438128A3 (en) 2024-11-13
CN107250348A (zh) 2017-10-13
JP2020182880A (ja) 2020-11-12
AU2015355187A1 (en) 2017-06-29
HK1245327A1 (zh) 2018-08-24
SG10201914058QA (en) 2020-03-30
US10926001B2 (en) 2021-02-23
AU2019240603A1 (en) 2019-10-17
MX2017007243A (es) 2018-01-25
MY184931A (en) 2021-04-30
MX2023001655A (es) 2023-04-24
JP2017538411A (ja) 2017-12-28
HK1250515A1 (zh) 2018-12-21
GB2569056A (en) 2019-06-05
US11000629B2 (en) 2021-05-11
US20230181797A1 (en) 2023-06-15
CA2969707C (en) 2019-08-20
EP3227431C0 (en) 2025-01-29
CO2017006640A2 (es) 2017-11-21
US20210322643A1 (en) 2021-10-21
CN107250348B (zh) 2021-09-03
KR20210043024A (ko) 2021-04-20
US20180154043A1 (en) 2018-06-07
JP6791854B2 (ja) 2020-11-25
ZA201703907B (en) 2023-03-29
GB2569056B (en) 2020-01-01
IL287488A (en) 2021-12-01
NZ733433A (en) 2019-08-30
JP2019088299A (ja) 2019-06-13
US11596714B2 (en) 2023-03-07
PH12017501009B1 (en) 2022-01-21
KR20180136587A (ko) 2018-12-24
IL252613B (en) 2021-12-01
KR20170098844A (ko) 2017-08-30
SG11201704502RA (en) 2017-06-29
KR20180136588A (ko) 2018-12-24
IL252613A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
PH12017501009A1 (en) Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells
MX2015014408A (es) Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
MX385333B (es) Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas.
CO2017000510A2 (es) Constructos de car
BR112017000939A2 (pt) tratamento de câncer usando um receptor antigênico quimérico de cll-1
MX394222B (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX2015000990A (es) Analogos del glucagon.
MX2017010159A (es) Vector que expresa conjuntamente vacunas y moléculas coestimuladoras.
MX2016010215A (es) Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
PE20130815A1 (es) Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos
IL274691A (en) Transformed human cells inhibited for expression of mhc i and mhc ii cell membrane receptors and uses thereof
NZ721835A (en) An osseointegrable device
PH12019500949A1 (en) Ror-gamma modulators
EA201692395A1 (ru) Новые соединения
MX386476B (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
NZ719745A (en) Soluble fc gamma receptor for treatment of autoimmune bullous diseases
CY1124859T1 (el) Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων
EA201990543A1 (ru) Композиции и способы репрограммирования т-клеточных рецепторов с помощью гибридных белков
AR096092A1 (es) ANTICUERPOS ANTI-IGF-1R CON ABOLICIÓN DE LA UNIÓN AL FcRn Y SU UTILIZACIÓN EN EL TRATAMIENTO DE ENFERMEDADES OCULARES VASCULARES